Mylan Technologies, Inc. v. Zydus Noveltech, Inc.

CourtVermont Superior Court
DecidedJanuary 24, 2012
DocketS0041
StatusPublished

This text of Mylan Technologies, Inc. v. Zydus Noveltech, Inc. (Mylan Technologies, Inc. v. Zydus Noveltech, Inc.) is published on Counsel Stack Legal Research, covering Vermont Superior Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Mylan Technologies, Inc. v. Zydus Noveltech, Inc., (Vt. Ct. App. 2012).

Opinion

Mylan Technologies, Inc. v. Zydus Noveltech, Inc., No. S0041-09 CnC (Crawford, J., Jan. 24, 2012)

[The text of this Vermont trial court opinion is unofficial. It has been reformatted from the original. The accuracy of the text and the accompanying data included in the Vermont trial court opinion database is not guaranteed.] STATE OF VERMONT

SUPERIOR COURT CIVIL DIVISION Chittenden Unit Docket No. S0041-09 CnC

MYLAN TECHNOLOGIES, INC. and MYLAN INC. Plaintiffs

v.

ZYDUS NOVELTECH, INC., SHARAD K. GOVIL, CADILA HEALTHCARE, LTD., PANKAJ PATEL and SUNIL ROY Defendants

DECISION ON MOTIONS TO DISMISS (PERSONAL JURISDICTION)

This case involves a dispute between two companies that develop or manufacture transdermal patches (devices for the delivery of medication through the skin). Plaintiffs Mylan Technologies, Inc. and its parent company Mylan, Inc. (collectively, “Mylan”) allege that defendant Dr. Sharad Govil took important trade secrets when he left his position as a senior Mylan executive and scientist and joined defendant Zydus Noveltech, Inc. (Zydus). Mylan asserts that Dr. Govil’s actions constitute breach of a trade secrets contract (Count I), breach of the covenant of good faith and fair dealing (Count II), misappropriation of trade secrets (Count IV), breach of fiduciary duty (Count V), and unfair competition (Count VI). Mylan also alleges that Zydus’s parent company Cadila Healthcare, Ltd. (Cadila),1 Cadila’s Chairman Pankaj Patel, and Cadila’s head of research and development Sunil Roy (collectively, the “Indian defendants”) and Zydus tortiously interfered with the trade secrets contract between Dr. Govil and Mylan (Count III), misappropriated trade secrets (Count IV), and engaged in unfair competition (Count VI).

On May 25, 2011, Cadila filed a motion to dismiss, arguing, among other things, that it is not subject to personal jurisdiction in Vermont. Also on that date, the individual defendants filed a similar motion to dismiss, arguing that the court lacks personal jurisdiction over them.2 Mylan filed separate oppositions (one opposing Cadila’s motion and one opposing Patel and Roy’s motion) on July 11, 2011. Cadila, Patel and Roy filed separate replies on August 22, 2011. Mylan filed a single surreply on September 7, 2011. The Indian defendants together filed their own surreply on September 22, 2011. The 1 To be precise, it appears that Cadila is in fact Zydus’s grandparent, since it seems undisputed that the Irish company ZIPL is the majority owner of Zydus, and ZIPL is in turn a wholly-owned subsidiary of the Indian company Cadila. 2 The corporate and individual Indian defendants also moved to dismiss for insufficient or untimely service of process. The court understands that service of process upon the Indian defendants under the Hague Convention is now complete. The court therefore addresses here only the issues of personal jurisdiction. court has considered the parties’ filings as well as their arguments at a hearing held on January 17, 2012.

APPLICABLE STANDARD

“A court has discretion to decide a pretrial motion to dismiss for lack of personal jurisdiction on the basis of affidavits alone, to permit discovery, and to conduct an evidentiary hearing.” Godino v. Cleanthes, 163 Vt. 237, 239 (1995) (citing Roman Catholic Diocese of Burlington, Inc. v. Paton Insulators, Inc., 146 Vt. 294, 296 (1985)). “It is preferable to conduct an evidentiary hearing on the merits of the motion where there are questions of credibility or disputed issues of fact.” Id. When a 12(b)(2) motion is decided without such a hearing, then the court “must consider the pleadings and affidavits in a light most favorable to the plaintiff.” N. Sec. Ins. Co. v. Mitec Elecs., Ltd., 2008 VT 96, ¶ 15, 184 Vt. 303. However, the plaintiff bears the burden of showing that the court has personal jurisdiction over the defendant. See N. Aircraft, Inc. v. Reed, 154 Vt. 36, 40 (1990); 5B Wright, Miller & Kane, supra, § 1351 (“[T]he plaintiff bears the burden to establish the court’s jurisdiction . . . .”). To meet its burden, the plaintiff need only make “a prima facie showing of jurisdiction, or, in other words, demonstrate facts which would support a finding of jurisdiction.” Mitec, 2008 VT 96, ¶ 15 (quoting Godino, 163 Vt. at 239). “Personal jurisdiction must be proved independently as to each defendant.” Id. (citing Schwartz v. Frankenhoff, 169 Vt. 287, 294 (1999)).

BACKGROUND

For present purposes, there does not appear to be any dispute with respect to the facts bearing on the jurisdictional questions.3 The following background is based on the allegations in the First Amended Complaint and the factual assertions in the parties’ filings.

Mylan, Inc. is a Pennsylvania corporation and is in the pharmaceutical business. First Am. Compl. ¶ 1 (filed Nov. 30, 2009). Mylan, Inc.’s wholly-owned subsidiary, Mylan Technologies, Inc., is located in St. Albans, Vermont and is involved in the design, development, and manufacture of transdermal drug delivery systems. Id. ¶ 2. Dr. Sharad Govil is a Vermont resident and was a senior executive and senior scientist at Mylan for approximately thirteen years prior to his resignation in September 2006. Id. ¶¶ 4, 26. He had in-depth knowledge of Mylan’s trade secret and confidential information. Id. At the commencement of his employment, Dr. Govil signed a Trade Secrets and Invention Agreement, under which he agreed not to disclose Mylan’s

3 Cadila argued in its motion to dismiss that some of Mylan’s jurisdictional allegations are “demonstrably false.” Cadila’s Mot. to Dismiss at 21 (filed May 25, 2011). Specifically, Cadila attacked the allegations in paragraph 11 of Mylan’s complaint that Cadila is a “majority owner of Zydus” and that “high-level representatives of Cadila traveled to Vermont in connection with their efforts to recruit Govil.” In their motion, defendants Patel and Roy also denied that they ever physically came to Vermont to recruit Dr. Govil. Patel and Roy’s Mot. to Dismiss at 6 (filed May 25, 2011). The parties do not now dispute the ownership relationship between Cadila and Zydus or the facts that Mr. Patel has never physically traveled to Vermont and Mr. Roy has only traveled to Vermont once.

2 confidential information and trade secrets, and also agreed to a restriction on his business activities for five years after the termination of his employment. Id. ¶¶ 20–24.

Cadila is an Indian pharmaceutical company and a significant manufacturer of generic drugs. Id. ¶ 6. In December 2005 or January 2006, Cadila’s head of Research and Development, Mr. Roy—a citizen and resident of India—placed a telephone call from India to Dr. Govil at Govil’s home in Vermont. See id. ¶¶ 8, 31; see also Mylan’s Opp’n to Cadila’s Mot. to Dismiss at 20 (filed July 11, 2011). In that call, Mr. Roy sought to “initiate discussion regarding a collaboration” between Mylan and Cadila to develop and manufacture transdermal delivery products. First Am. Compl. ¶ 31. Subsequently, Dr. Govil led an internal team at Mylan to assess the opportunity presented and to recommend whether a relationship with Cadila would be advantageous for Mylan. Id. ¶ 32. Mylan’s discussions with Cadila about a potential collaboration were active and ongoing during the first quarter of 2006, with Dr. Govil representing Mylan’s interests. Id. ¶¶ 33, 34.

In April 2006, prior to the conclusion of Mylan and Cadila’s discussions, Mr. Roy called Dr. Govil again to coordinate a discussion between Dr. Govil and Cadila’s Chairman, Mr. Patel. See id. ¶ 33; Mylan’s Opp’n to Patel and Roy’s Mot. to Dismiss at 6 (citing Govil Tr. 81:1–82:11, Oct. 26, 2009); Mylan’s Opp’n to Cadila’s Mot. to Dismiss at 20 (citing Govil Tr. 77:6–78:20; 80:21–81:14). Like Mr. Roy, Mr. Patel is a resident and citizen of India. First Am. Compl. ¶ 7. Mr. Roy sought to gauge Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Calder v. Jones
465 U.S. 783 (Supreme Court, 1984)
Burger King Corp. v. Rudzewicz
471 U.S. 462 (Supreme Court, 1985)
Marine Midland Bank, N.A. v. James W. Miller
664 F.2d 899 (Second Circuit, 1981)
Abraham Alvarado-Morales v. Digital Equipment Corp.
843 F.2d 613 (First Circuit, 1988)
Imo Industries, Inc. v. Kiekert Ag
155 F.3d 254 (Third Circuit, 1998)
Consulting Engineers Corp. v. Geometric Ltd.
561 F.3d 273 (Fourth Circuit, 2009)
In re R.W. and N.W.
2011 VT 124 (Supreme Court of Vermont, 2011)
Prive v. Vermont Asbestos Group
2010 VT 2 (Supreme Court of Vermont, 2010)
Northern Security Insurance Co. v. Mitec Electronics, Ltd.
2008 VT 96 (Supreme Court of Vermont, 2008)
Roquette America, Inc. v. Gerber
651 N.W.2d 896 (Court of Appeals of Iowa, 2002)
C.S.B. Commodities, Inc. v. Urban Trend (HK) Ltd.
626 F. Supp. 2d 837 (N.D. Illinois, 2009)
Havill v. Woodstock Soapstone Co.
783 A.2d 423 (Supreme Court of Vermont, 2001)
Godino v. Cleanthes
656 A.2d 991 (Supreme Court of Vermont, 1995)

Cite This Page — Counsel Stack

Bluebook (online)
Mylan Technologies, Inc. v. Zydus Noveltech, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/mylan-technologies-inc-v-zydus-noveltech-inc-vtsuperct-2012.